Summary & Overview
HCPCS J9276: Injection, zanidatamab-hrii, 2 mg
HCPCS Level II code J9276 identifies an injection of zanidatamab-hrii in 2 mg units, covering administration of a targeted monoclonal antibody formulation. Nationally, a distinct HCPCS code for this biologic matters for accurate claims processing, utilization monitoring, and pricing transparency as oncology and specialty drug use grows.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how the code is used in billing lines, typical sites of service, common modifiers associated with injectable biologics, and which payers are relevant for coverage and claims adjudication. The publication outlines available benchmarks where present, highlights recent coding or policy updates if applicable, and supplies clinical context about the drug formulation and administration setting.
The article is intended for revenue cycle leaders, clinical billing staff, and policy analysts seeking a national-level reference on coding and billing practices for this injectable biologic. Data not available in the input will be noted as such in appropriate sections.
Billing Code Overview
HCPCS Level II code J9276 represents an injection of zanidatamab-hrii, 2 mg. This code denotes a single unit of the specified monoclonal antibody preparation administered by injection.
Service Type: Drug administration (intravenous or subcutaneous injectable biologic)
Typical Site of Service: Hospital outpatient department, physician office infusion suite, or ambulatory infusion center
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J9276 (Injection, zanidatamab-hrii, 2 mg) is an adult oncology patient with an advanced or metastatic HER2-expressing solid tumor for which zanidatamab-hrii is indicated. The clinical workflow begins with an oncologist evaluation in an outpatient infusion center or hospital outpatient department where treatment decisions are based on prior pathology, HER2 testing results, prior lines of therapy, and performance status. Pre-infusion tasks include verification of the prescription, dose calculation by weight or body surface area if required, pharmacy compounding or vial preparation under sterile conditions, and review of concurrent medications and allergy history. On the day of infusion, nursing performs baseline vital signs, consent verification, and pre-medication administration per institutional protocol (for example, antihistamines, antipyretics, or corticosteroids if infusion reaction risk exists). The drug is administered intravenously by infusion nursing staff using an appropriate infusion pump and line; infusion time and rate are documented. During and after infusion, the patient is monitored for infusion-related reactions and other adverse events, with vital signs recorded at defined intervals. Post-infusion documentation includes administered units of J9276, lot number, expiration date, route, site of service, and any administered pre-medications or management of adverse reactions. Typical sites of service are outpatient infusion centers, hospital outpatient departments, and occasionally inpatient settings for patients requiring higher acuity monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|